The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases

Background: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and scleroderma, predominantly affect women and are characterized by systemic inflammation, leading to organ failure. Prolactin (PRL), a hormone produced by the pituitary gland and lym...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohamed Ismail Abdelkarem, HM Fayed, Wael Abd El-Mohsen Abady, Eman Abulhagag Mohammed Mahmoud
Format: Article
Language:English
Published: South Valley University, Faculty of Medicine 2025-07-01
Series:SVU - International Journal of Medical Sciences
Subjects:
Online Access:https://svuijm.journals.ekb.eg/article_382169.html
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832086837209858048
author Mohamed Ismail Abdelkarem
HM Fayed
Wael Abd El-Mohsen Abady
Eman Abulhagag Mohammed Mahmoud
author_facet Mohamed Ismail Abdelkarem
HM Fayed
Wael Abd El-Mohsen Abady
Eman Abulhagag Mohammed Mahmoud
author_sort Mohamed Ismail Abdelkarem
collection DOAJ
description Background: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and scleroderma, predominantly affect women and are characterized by systemic inflammation, leading to organ failure. Prolactin (PRL), a hormone produced by the pituitary gland and lymphocytes, significantly affects immune regulation and is implicated in the pathophysiology of these diseases. Objectives: This study aimed to evaluate the relationship between PRL levels and disease activity in RA, SLE, and scleroderma. Patients and methods: A cross-sectional case-control study involved 150 premenopausal women (50 with RA, 30 with SLE, and 20 with scleroderma) and 50 age-matched healthy controls. Clinical disease activity assessments (DAS28 for RA, SLEDAI for SLE, and MRSS for scleroderma) and laboratory estimation of serum PRL level were conducted. Results: The mean PRL levels in RA (26.17 ng/ml), SLE (25.23 ng/ml), and scleroderma (32.07 ng/ml) were significantly higher than controls (15.48 ng/ml) (P < 0.001). 42% of RA patients, 30% of SLE patients, and 50% of scleroderma patients had elevated PRL levels. Hyperprolacinemia is correlated with disease activity (DAS28 (r = 0.493, p = 0.0001), SLEDAI (r = 0.546, p = 0.002), and MRSS (r = 0.893, p = 0.0001), respectively). Conclusion: Serum PRL levels were significantly elevated in RA, SLE, and scleroderma, which is consistent with disease activity scores. Regular monitoring may be necessary because of the potential of PRL to function as a marker of disease activity. The therapeutic potential of dopamine agonists in autoimmune diseases warrants further investigation, as they have the potential to reduce flare-ups and organ involvement.
format Article
id doaj-art-38ae996a574a4da2b79832f1d9c6257d
institution Kabale University
issn 2735-427X
2636-3402
language English
publishDate 2025-07-01
publisher South Valley University, Faculty of Medicine
record_format Article
series SVU - International Journal of Medical Sciences
spelling doaj-art-38ae996a574a4da2b79832f1d9c6257d2025-02-06T09:45:18ZengSouth Valley University, Faculty of MedicineSVU - International Journal of Medical Sciences2735-427X2636-34022025-07-0172529544https://doi.org/10.21608/svuijm.2024.299939.1904The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic DiseasesMohamed Ismail Abdelkarem 0HM Fayed 1 Wael Abd El-Mohsen Abady2 Eman Abulhagag Mohammed Mahmoud 3Rheumatology and Rehabilitation Department, Faculty of Medicine, Al-Azhar University (Assiut Branch), Assuit, Egypt.Clinical Pathology Department, Faculty of Medicine, South Valley University, Qena, Egypt Physical Medicine, Rheumatology and Rehabilitation Department, Faculty of Medicine, South Valley University, Qena, Egypt. Physical Medicine, Rheumatology and Rehabilitation Department, Faculty of Medicine, South Valley University, Qena, Egypt.Background: Autoimmune rheumatic diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), and scleroderma, predominantly affect women and are characterized by systemic inflammation, leading to organ failure. Prolactin (PRL), a hormone produced by the pituitary gland and lymphocytes, significantly affects immune regulation and is implicated in the pathophysiology of these diseases. Objectives: This study aimed to evaluate the relationship between PRL levels and disease activity in RA, SLE, and scleroderma. Patients and methods: A cross-sectional case-control study involved 150 premenopausal women (50 with RA, 30 with SLE, and 20 with scleroderma) and 50 age-matched healthy controls. Clinical disease activity assessments (DAS28 for RA, SLEDAI for SLE, and MRSS for scleroderma) and laboratory estimation of serum PRL level were conducted. Results: The mean PRL levels in RA (26.17 ng/ml), SLE (25.23 ng/ml), and scleroderma (32.07 ng/ml) were significantly higher than controls (15.48 ng/ml) (P < 0.001). 42% of RA patients, 30% of SLE patients, and 50% of scleroderma patients had elevated PRL levels. Hyperprolacinemia is correlated with disease activity (DAS28 (r = 0.493, p = 0.0001), SLEDAI (r = 0.546, p = 0.002), and MRSS (r = 0.893, p = 0.0001), respectively). Conclusion: Serum PRL levels were significantly elevated in RA, SLE, and scleroderma, which is consistent with disease activity scores. Regular monitoring may be necessary because of the potential of PRL to function as a marker of disease activity. The therapeutic potential of dopamine agonists in autoimmune diseases warrants further investigation, as they have the potential to reduce flare-ups and organ involvement.https://svuijm.journals.ekb.eg/article_382169.htmlrheumatoid arthritis systemic lupus erythematosussystemic sclerosis das28 sledai
spellingShingle Mohamed Ismail Abdelkarem
HM Fayed
Wael Abd El-Mohsen Abady
Eman Abulhagag Mohammed Mahmoud
The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases
SVU - International Journal of Medical Sciences
rheumatoid arthritis systemic lupus erythematosus
systemic sclerosis das28 sledai
title The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases
title_full The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases
title_fullStr The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases
title_full_unstemmed The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases
title_short The Role of Prolactin as a Disease Activity Indicator in Some Rheumatic Diseases
title_sort role of prolactin as a disease activity indicator in some rheumatic diseases
topic rheumatoid arthritis systemic lupus erythematosus
systemic sclerosis das28 sledai
url https://svuijm.journals.ekb.eg/article_382169.html
work_keys_str_mv AT mohamedismailabdelkarem theroleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT hmfayed theroleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT waelabdelmohsenabady theroleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT emanabulhagagmohammedmahmoud theroleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT mohamedismailabdelkarem roleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT hmfayed roleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT waelabdelmohsenabady roleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases
AT emanabulhagagmohammedmahmoud roleofprolactinasadiseaseactivityindicatorinsomerheumaticdiseases